HISTORICAL FACTS: Astrazeneca - Caught on Camera

EGFR Lung Cancer Patients Await a November 14 FDA Decision on Ivonescimab Plus Chemotherapy After Tagrisso Stops Working

The FDA is due to decide by Nov. 14 on ivonescimab plus chemotherapy for EGFR lung cancer after Tagrisso. What patients and families can ask now.

Medical Daily · Oct 1

AstraZeneca Seeks FDA Approval for Savolitinib Plus Tagrisso in Lung Cancer That Resists Tagrisso Through MET Changes

AstraZeneca has filed for FDA approval of savolitinib plus Tagrisso for EGFR-mutated lung cancer with MET-driven resistance. Full SAFFRON data are pending.

Medical Daily · Oct 1

A $2 Billion Reason Why AstraZeneca Stock Is Down Today

AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in AZN shares today? Let’s find out!

Barchart · Sep 29

Global Market: European shares rise as oil slide boosts risk appetite

European shares rose as technology stocks led gains and falling oil prices eased inflation concerns. The STOXX 600 advanced 0.56%, while investors also tracked the upcoming Trump-Xi meeting.

The Economic Times · Sep 21

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is…

The Economic Times · Sep 21

First-Line Enhertu Delayed HER2-Mutant Lung Cancer Progression by Six Months Over Keytruda Plus Chemotherapy, but Survival Remains Unsettled

Enhertu delayed HER2-mutant lung cancer progression by a median of six months versus Keytruda plus chemo in a Phase 3 trial. Survival is unresolved.

Medical Daily · Sep 17

NHS Approves Breast Cancer Drug Rejected Two Years Ago After Trump Deal Raises NICE Spending Limit

NICE has approved Enhertu for eligible women in England after a new drug deal and higher cost-effectiveness threshold made the treatment affordable for NHS funding.

International Business Times UK · Sep 17

New cancer treatment gives lifeline to stranded women

Women who suffer from breast cancer, endometriosis or other conditions that require ovarian suppression now have a new drug included on the PBS.

AAP · Sep 17

An Injected COPD Drug Cut Flare Ups About Thirty Percent in Patients Whose Inhalers Were Not Enough

Two Phase III trials of tozorakimab cut moderate and severe COPD flare-ups by roughly 30 percent. An FDA decision is expected in early 2027.

Medical Daily · Sep 9

Breast Cancer Drug Wins Accelerated Approval Four Months After FDA Advisers Voted Six to Three Against It

FDA granted camizestrant accelerated approval for ESR1-mutated breast cancer months after its advisory committee voted against the application.

Medical Daily · Sep 9